Bayer's finerenone successful in late-stage study in T2D patients with kidney disease

• Bayer (OTCPK:BAYRY -1.1%) announces positive results from a large-scale Phase 3 clinical trial, FIDELIO-DKD, evaluating finerenone on top of standard-of-care (SOC) treatment in type 2 diabetes (T2D) patients with chronic kidney disease (CKD).
• The study met the primary endpoint demonstrating that treatment with finerenone delayed the progression of CKD by reducing the combined risk of time-to-first-occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) of at least 40% from baseline over a period of at least four weeks, or renal death compared to placebo plus SOC treatment.
• Finerenone also reduced the risk of a composite of time-to-first-occurrence of cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, or heart failure hospitalization, a key secondary endpoint.
• The company says finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to reduce the harmful effects of mineralocorticoid receptor overactivation, a major driver of kidney and heart damage.
• Bayer recently launched another large-scale Phase 3, FINEARTS-HF, assessing finerenone in symptomatic heart failure patients with at least 40% left ventricular ejection fraction.